Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2023
ABPI response to Government Statutory Scheme rise
2 March 2023 - The Government has confirmed plans to raise the revenue clawback rate paid by pharmaceutical firms subject ...
Posted by Michael Wonder on 01 Mar 2023
ABPI sets out new proposals to support the NHS and economic growth
1 March 2023 - The pharmaceutical industry’s offer includes an annual £1 billion boost to the NHS as well as an ...
Posted by Michael Wonder on 17 Feb 2023
High drug prices are not justified by industry’s spending on research and development
15 February 2023 - Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative ...
Posted by Michael Wonder on 07 Feb 2023
The EU butts heads with big pharma to make medicines cheaper
2 February 2023 - The bloc’s pharma reform aims to get new drugs to patients faster, for less money. But it ...
Posted by Michael Wonder on 06 Feb 2023
Pharma industry urges halt to further rises in record revenue clawbacks
2 February 2023 - The pharmaceutical industry is calling on the government to scrap plans to raise the statutory revenue clawback ...
Posted by Michael Wonder on 20 Jan 2023
UK's voluntary scheme for branded medicines, pricing and access (VPAS) faces a potential crisis
19 January 2023 - The UK has a “voluntary scheme for branded medicines, pricing, and access” or VPAS, which sets a ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 16 Jan 2023
AbbVie and Eli Lilly, two of the world’s largest pharmaceutical companies, have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks
16 January 2023 - AbbVie and Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access, a ...
Posted by Michael Wonder on 11 Dec 2022
Prices soar for antibiotics as desperate parents search for strep A medicine
11 December 2022 - Drug companies have been accused of “cartel behaviour” for increasing the costs of antibiotics during the ...
Posted by Michael Wonder on 17 Nov 2022
A tussle over medicines pricing is looming in Britain
15 November 2022 - Agreement to limit the size of the NHS drugs bill under strain. ...
Posted by Michael Wonder on 18 Mar 2022
Update to the statutory scheme to control the costs of branded health service medicines
15 March 2022 - The UK Government is seeking views on its proposal to increase the rate of payments made ...
Posted by Michael Wonder on 03 Feb 2022
Britain fines firms $47 million over price surge for NHS nausea pill
3 February 2022 - Britain's competition watchdog on Thursday fined five firms a total of 35 million pounds ($47.5 million) ...
Posted by Michael Wonder on 02 Nov 2021
Pricing vaccines and drugs in Europe: worth differentiating?
1 November 2021 - The COVID-19 pandemic has recently brought to the forefront the vital importance of vaccines, of which Europe ...
Posted by Michael Wonder on 05 Aug 2021
Pfizer epilepsy drug prices were 'unfairly high,' UK review finds
5 August 2021 - Britain's competition watchdog is sticking with its view that Pfizer and Flynn Pharma broke the law ...
Posted by Michael Wonder on 29 Jul 2021
Advanz and private equity groups fined for 1,000 per cent drug price hike
29 July 2021 - Regulator penalises pharma company and buyout firms Cinven and Hg after NHS hit by ‘unfair’ rises. ...